Medical disclaimer: Educational content only, not medical advice. If you have a family history of cancer, speak to a certified genetic counselor or your physician. Consumer genetic testing is not a substitute for clinical hereditary cancer testing.
Both a clinical hereditary cancer panel and a consumer whole genome sequence will read the BRCA1 gene. Both will report variants in it. On paper, the genome reads vastly more DNA and costs about the same.
And yet, if you have a family history of breast cancer and you are trying to decide whether you carry a pathogenic variant, one of these tests is the right tool and the other is not. Understanding exactly why is one of the most useful things you can learn about genetic testing.
A hereditary cancer panel is a clinical diagnostic test: physician-ordered, narrow in scope, validated to detect every variant class in its target genes, interpreted by clinical experts, and delivered with genetic counseling. A consumer whole genome sequence is a data product: broader, cheaper per base, and yours to keep — but not validated for clinical decisions and prone to specific technical blind spots that matter enormously for cancer genes. They are complementary. They are not substitutes.
What a hereditary cancer panel actually is
A targeted multigene panel that sequences a defined set of cancer predisposition genes to clinical standards. Typical panels run 25 to 100+ genes.
The core genes are well established. For hereditary breast and ovarian cancer, ESMO guidance specifies panels comprising clinically validated genes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11 and TP53. Lynch syndrome and polyposis panels add their own gene sets.
Crucially, ESMO also highlights that marketed screening panels increasingly incorporate genes beyond BRCA1/2, and that associated cancer risk varies greatly with each gene — which is why comprehensive genetic counseling is needed to differentiate the risks attached to different genes.
That last point is easy to skim past and is genuinely important. A pathogenic BRCA1 variant and a pathogenic CHEK2 variant are both "positive" results. They imply wildly different lifetime risks and wildly different management. A report that lists both without that context is nearly useless.
The four things a clinical panel does that a consumer genome does not
1. It detects every class of variant, not just single-letter changes
This is the technical heart of the matter, and it is the reason consumer sequencing cannot simply be substituted in.
Pathogenic variants come in several forms:
- Single nucleotide variants — one letter changed. Consumer WGS handles these well.
- Small insertions and deletions — a few letters added or removed. Generally handled adequately.
- Large rearrangements — entire exons deleted or duplicated. This is the problem.
Large rearrangements are a meaningful fraction of pathogenic variants in some cancer genes. They are detected with a specific technique, MLPA (multiplex ligation-dependent probe amplification), or with copy-number analysis explicitly validated for the purpose. ESMO guidance is explicit that APC analysis should include large rearrangements, and that a multigene analysis of APC, MUTYH (all exons), POLE, POLD1 and NTHL1 is recommended for suspected polyposis.
Standard 30x consumer whole genome sequencing is not reliably validated for calling these events in a clinical context. A consumer WGS report can say "no pathogenic BRCA1 variant found" while a whole exon of BRCA1 is missing from that person's genome. The read depth is adequate; the analysis pipeline and its validation are not built for it.
This is the false-negative that matters. A person with a real, pathogenic, actionable large deletion in a cancer gene can receive a clean consumer WGS report. They then reasonably conclude they are not at hereditary risk. That conclusion can be lethal, and it is not a hypothetical — it is the predictable consequence of using a data product as a diagnostic.
2. It is interpreted against clinical evidence, by people
Finding a variant is the easy part. Deciding whether it is pathogenic, benign, or of uncertain significance is where the expertise lives.
Clinical labs classify variants using the ACMG framework, drawing on population frequency databases, functional studies, segregation data in affected families, and internal databases of previously classified variants. Variant classification changes over time as evidence accrues, and clinical labs issue amended reports when it does.
Consumer WGS platforms typically annotate against public databases and stop there. Nobody reclassifies your variant in three years and writes to tell you.
3. It comes with genetic counseling
Not a nice-to-have. A pathogenic BRCA1 result initiates a cascade of decisions — enhanced screening, risk-reducing surgery, reproductive planning, and testing for siblings, children and parents who each have a 50% chance of carrying the same variant.
Making those decisions from a PDF you downloaded is not a fair position to put yourself in.
4. It is ordered in a clinical context, which means insurance and follow-through
A physician-ordered panel meeting NCCN criteria is frequently covered by insurance. A positive result flows directly into a management plan. A consumer result sits in your inbox and generally must be confirmed by a clinical test before any doctor will act on it — meaning you may end up paying twice.
So what is whole genome sequencing genuinely good for?
Having been appropriately harsh, it is worth being fair. Consumer WGS does several things a cancer panel cannot, and they are real.
- Breadth beyond cancer. A panel reads 30–100 genes. A genome reads all ~20,000, plus everything between them. Pharmacogenomics, carrier status, metabolic variants, traits — a cancer panel returns none of this.
- You own the raw data. FASTQ, BAM and VCF files, permanently. You can re-analyse them with any tool as science improves. A clinical panel gives you a report, not usually a dataset.
- Future-proofing. A panel reads the genes someone selected in 2026. When a new cancer gene is characterised in 2032, your existing genome data already contains it. Your panel does not.
- Cost per base. A genome is dramatically cheaper per unit of data, and increasingly comparable in absolute price to a comprehensive panel.
- No gatekeeping. You do not need to meet NCCN criteria or persuade a physician. Given that research suggests current criteria may miss carriers who would benefit, and that access barriers keep most eligible people from ever being tested, this genuinely matters.
The honest comparison
| Hereditary cancer panel | Consumer whole genome | |
|---|---|---|
| Genes covered | 25–100+, cancer-specific | All of them, plus non-coding DNA |
| Large rearrangement detection | Yes — validated (MLPA / CNV) | Not clinically validated |
| Variant interpretation | Clinical experts, ACMG framework | Automated database annotation |
| Reclassification over time | Yes — labs issue amended reports | No |
| Genetic counseling | Standard | Not included |
| Insurance coverage | Often, if criteria met | No |
| Raw data ownership | Usually not | Yes — FASTQ/BAM/VCF |
| Cost | $0–$300 with insurance; $250–$2,000 without | ~$169–$495 |
| Actionable for medical decisions? | Yes | Not on its own |
How to actually decide
If you have a concerning family history of cancer — early-onset diagnoses, multiple affected relatives, ovarian or pancreatic cancer, male breast cancer, or a known familial variant — get a clinical hereditary cancer panel. Ask your physician, or go directly to a genetic counselor. This is not the place to economise, and a consumer test is not an acceptable substitute.
If you are broadly curious about your genome and cancer risk is one of several interests, whole genome sequencing is excellent value and gives you far more, permanently.
If you want both, that is a legitimate and increasingly common strategy: a clinical panel for the medical question, a genome for everything else and for the long term.
If a consumer test flags something in a cancer gene, do not panic and do not act. Take it to a genetic counselor and get it confirmed clinically. Consumer results are a reason to investigate, never a basis for surgery.
Whole genome sequencing, done properly
30x clinical-grade coverage with full FASTQ, BAM and VCF files included. Read every gene, own your data permanently, and give a genetic counselor something real to work with.
Explore Dante Labs Whole Genome Sequencing → Use code GENOME for 10% off · Affiliate link · Not a substitute for clinical hereditary cancer testingThe bottom line
A clinical hereditary cancer panel is a medical test. A consumer whole genome sequence is a data product. Both are legitimate; they are built for different jobs.
The genome gives you more information. The panel gives you information you can safely act on. If your question is "should I have a prophylactic mastectomy," you need the second one — and no amount of raw sequencing data changes that.
Sources
- UnitedHealthcare. Genetic Testing for Hereditary Cancer, 2026 — summarising ESMO and NCCN guidance.
- Carelon Medical Benefits Management. Appropriate Use Criteria: Hereditary Cancer Testing, 2026.
- Identification of Patients at Elevated Cancer Risk through a Community-Based Genetic Testing Program. PMC.
- Chronos Genomics. Cheapest Whole Genome Sequencing 2026.